Home / Science / New Vaccine Targets Deadly Pneumonia Strain
New Vaccine Targets Deadly Pneumonia Strain
5 Apr
Summary
- Novel vaccine developed at BITS Pilani targets Streptococcus pneumoniae.
- The experimental vaccine uses AI to identify and combine protein fragments.
- Mice studies show the vaccine is non-toxic and elicits immune response.
A novel experimental vaccine designed to combat Streptococcus pneumoniae, the bacterium responsible for severe infections like pneumonia, meningitis, and sepsis, has been developed by researchers at BITS Pilani's Hyderabad campus.
This innovative approach eschews traditional methods, instead utilizing advanced computational tools and artificial intelligence to design a synthetic 'multiepitope' vaccine. The process involved identifying and combining key protein fragments recognized by the human immune system from bacterial outer cell wall proteins.
This digitally designed vaccine blueprint was then synthesized and tested in mice. Results indicated that the experimental vaccine elicited a strong immune response without causing toxicity, specifically to red blood cells. This demonstrates its potential for further development.
Future research will involve testing the vaccine in larger animal models and conducting challenge studies to confirm its efficacy in neutralizing live bacteria and preventing infection. The goal is a strain-independent pneumococcal vaccine.
